DK0998495T3 - Amyloid-beta-protein (glubulær samling og anvendelser deraf) - Google Patents

Amyloid-beta-protein (glubulær samling og anvendelser deraf)

Info

Publication number
DK0998495T3
DK0998495T3 DK98905006T DK98905006T DK0998495T3 DK 0998495 T3 DK0998495 T3 DK 0998495T3 DK 98905006 T DK98905006 T DK 98905006T DK 98905006 T DK98905006 T DK 98905006T DK 0998495 T3 DK0998495 T3 DK 0998495T3
Authority
DK
Denmark
Prior art keywords
addls
activity
formation
amyloid beta
glubular
Prior art date
Application number
DK98905006T
Other languages
Danish (da)
English (en)
Inventor
Brett A Chromy
Mary P Lambert
Pat Wals
Grant A Krafft
William L Klein
Caleb E Finch
Todd Morgan
Ann Barlow
Irina Rozovsky
Original Assignee
Univ Northwestern
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern, Univ Southern California filed Critical Univ Northwestern
Application granted granted Critical
Publication of DK0998495T3 publication Critical patent/DK0998495T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK98905006T 1997-02-05 1998-02-05 Amyloid-beta-protein (glubulær samling og anvendelser deraf) DK0998495T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/796,089 US6218506B1 (en) 1997-02-05 1997-02-05 Amyloid β protein (globular assembly and uses thereof)
PCT/US1998/002426 WO1998033815A1 (fr) 1997-02-05 1998-02-05 PROTEINE AMYLOIDE β (ENSEMBLE GLOBULAIRE ET SES UTILISATIONS)

Publications (1)

Publication Number Publication Date
DK0998495T3 true DK0998495T3 (da) 2007-05-07

Family

ID=25167266

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98905006T DK0998495T3 (da) 1997-02-05 1998-02-05 Amyloid-beta-protein (glubulær samling og anvendelser deraf)

Country Status (12)

Country Link
US (2) US6218506B1 (fr)
EP (2) EP0998495B1 (fr)
JP (2) JP3512815B2 (fr)
AT (1) ATE349467T1 (fr)
AU (1) AU735825B2 (fr)
BR (1) BR9807185A (fr)
CA (1) CA2279555C (fr)
DE (1) DE69836740T2 (fr)
DK (1) DK0998495T3 (fr)
ES (1) ES2280090T3 (fr)
PT (1) PT998495E (fr)
WO (1) WO1998033815A1 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1187920A2 (fr) 1999-06-09 2002-03-20 Arch Development Corporation Genes, proteines et matieres de recombinaison de type prion et procedes associes
ES2235926T3 (es) * 1999-08-04 2005-07-16 The University Of Southern California Ensamblaje globular de proteina beta amiloide y sus usos.
PE20010978A1 (es) 1999-12-23 2001-09-14 Upjohn Co ENSAYOS Y METODOS DE DIAGNOSTICO QUE INVOLUCRAN CANALES DE SODIO COMO OBJETIVOS DE AMILOIDE ß O DE SUS AGREGADOS
EP1257584B2 (fr) * 2000-02-24 2013-03-06 Washington University St. Louis Anticorps humanises sequestrant un peptide amyloide beta
EP1309341A2 (fr) 2000-07-07 2003-05-14 Lars Lannfelt Prevention et traitement de la maladie d'alzheimer
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
EP1944040B1 (fr) * 2001-08-17 2012-08-01 Washington University Procédé d'analyse pour la maladie d'Alzheimer
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003279728B2 (en) * 2002-10-01 2007-09-27 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
WO2005110056A2 (fr) * 2004-05-14 2005-11-24 Northwestern University Compositions contenant des recepteurs d'addl, compositions et methodes associees
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1594969B1 (fr) * 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Immunisation active permettant de produire des anticorps contre a-beta soluble
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8250823B2 (en) 2003-08-26 2012-08-28 Ejot Gmbh & Co. Kg Dowels and methods for the assembly of insulating panels
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20080044356A1 (en) * 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
AU2005306997B2 (en) 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
WO2006066049A2 (fr) * 2004-12-15 2006-06-22 Neuralab Limited Anticorps humanises reconnaissant le peptide beta amyloide
CA2590337C (fr) * 2004-12-15 2017-07-11 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
EP1838349A1 (fr) * 2004-12-15 2007-10-03 Neuralab, Ltd. ANTICORPS AMYLOIDE beta UTILISES AFIN D'AMELIORER LA COGNITION
US8420093B2 (en) 2005-02-14 2013-04-16 Merck Sharp & Dohme Corp. Anti-ADDL monoclonal antibody and use thereof
US7731962B2 (en) * 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
TW200700432A (en) * 2005-03-05 2007-01-01 Abbott Gmbh & Co Kg Screening method, process for purifying of non-diffusible a β oligomers, selective antibodies against said non-diffusible a β oligomers and a process for manufacturing of said antibodies
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
WO2007016357A1 (fr) * 2005-07-29 2007-02-08 Regents Of The University Of Minnesota Recepteur du beta amyloide et ses utilisations
US20080014596A1 (en) * 2005-11-16 2008-01-17 Jasna Jerecic ADDL Binding to Hippocampal Neurons
KR101439828B1 (ko) * 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
KR20080090408A (ko) * 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
WO2007064917A2 (fr) 2005-11-30 2007-06-07 Abbott Laboratories Procedes de preparation de formes recombinees de la proteine beta-amyloide humaine et utilisation desdites proteines
EP2361638B1 (fr) * 2005-12-12 2014-01-15 AC Immune S.A. Anticorps monoclonaux spécifiques de A beta 1-42 avec des propriétés thérapeutiques
JP5033868B2 (ja) * 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP4876224B2 (ja) * 2006-06-05 2012-02-15 財団法人ヒューマンサイエンス振興財団 アミロイドβオリゴマー並びにその製造方法及び使用方法
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
ATE426174T1 (de) * 2006-07-28 2009-04-15 Vista Ventures Gmbh Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
UA95996C2 (ru) * 2007-01-18 2011-09-26 Эли Лилли Энд Компани Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
MX2009011127A (es) * 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
CN104761641A (zh) * 2007-06-12 2015-07-08 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
ES2401664T3 (es) 2007-07-12 2013-04-23 Acumen Pharmaceuticals, Inc. Procedimientos de modificación de oligómeros beta amiloides utilizando compuestos no peptídicos
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US9006283B2 (en) * 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
PT2238166E (pt) * 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
WO2009051220A1 (fr) * 2007-10-19 2009-04-23 Immunas Pharma, Inc. Anticorps capable de se lier spécifiquement à un oligomère aβ, et son utilisation
US8993714B2 (en) * 2007-10-26 2015-03-31 Imiplex Llc Streptavidin macromolecular adaptor and complexes thereof
WO2009079566A2 (fr) * 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Nouveaux polypeptides du récepteur de l'addl, polynucléotides et cellules hôtes pour une production recombinante
HUE031944T2 (en) * 2008-02-08 2017-08-28 Immunas Pharma Inc Antibodies capable of specific binding of amyloid β-oligomers and their use
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US9285363B2 (en) 2009-05-11 2016-03-15 Imiplex Llc Method of protein nanostructure fabrication
CN102574915B (zh) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
CN102596997B (zh) 2009-08-06 2015-06-03 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
EP2463369A4 (fr) 2009-08-07 2013-09-18 Kyowa Hakko Kirin Co Ltd Anticorps oligomère humanisé anti-substance b-amyloïde
CA2769464C (fr) 2009-08-07 2017-11-21 Kyowa Hakko Kirin Co., Ltd. Anticorps oligomere humanise anti-substance .beta.-amyloid
EP2368558A1 (fr) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Composés azo diminuant la formation et la toxicité d'intermédiaires d'agrégation beta-amyloïde
WO2011130377A2 (fr) 2010-04-15 2011-10-20 Abbott Laboratories Protéines de liaison à la bêta amyloïde
EP2593475B1 (fr) 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anticorps monoclonal anti-addl et ses utilisations
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
CN103782171B (zh) 2011-07-13 2016-12-14 默沙东公司 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途
WO2013164763A2 (fr) 2012-04-30 2013-11-07 Innovative Health Diagnostics Complexe biologique spécifique du dépistage de la maladie d'alzheimer in vitro et son utilisation
ES2915833T3 (es) 2014-01-31 2022-06-27 Cognition Therapeutics Inc Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular
KR102564384B1 (ko) 2014-07-10 2023-08-07 바이오악틱 에이비 개선된 Aβ 프로토피브릴 결합 항체
WO2024071361A1 (fr) * 2022-09-27 2024-04-04 株式会社カネカ Méthode d'évaluation d'activité d'inhibition ou de promotion de coagulation contre une protéine coagulante

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1298436T3 (da) 1992-10-26 2010-10-25 Elan Pharm Inc Fremgangsmåde til identificering af inhibitorforbindelser for frisætning af beta-amyloidpeptid (BAP)
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)

Also Published As

Publication number Publication date
PT998495E (pt) 2007-03-30
BR9807185A (pt) 2000-01-25
DE69836740D1 (de) 2007-02-08
AU6273598A (en) 1998-08-25
AU735825B2 (en) 2001-07-19
CA2279555C (fr) 2012-05-01
ES2280090T3 (es) 2007-09-01
JP2004091492A (ja) 2004-03-25
EP1808444A1 (fr) 2007-07-18
EP0998495B1 (fr) 2006-12-27
JP3512815B2 (ja) 2004-03-31
EP0998495A1 (fr) 2000-05-10
US6218506B1 (en) 2001-04-17
US20060166275A1 (en) 2006-07-27
ATE349467T1 (de) 2007-01-15
WO1998033815A1 (fr) 1998-08-06
US7638283B2 (en) 2009-12-29
JP2001501972A (ja) 2001-02-13
DE69836740T2 (de) 2007-10-11
CA2279555A1 (fr) 1998-08-06

Similar Documents

Publication Publication Date Title
DK0998495T3 (da) Amyloid-beta-protein (glubulær samling og anvendelser deraf)
HK1047944A1 (zh) 澱粉體乙等蛋白之球形組合及其使用
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
DE69841653D1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
NO931889L (no) Protease og beslektede DNA-forbindelser
DK1571208T3 (da) Fremgangsmåde til ny faktor IX-rensning
DE69833014D1 (de) Menschliche toll homologen
KR890700666A (ko) 혈관 항응고 단백질, 이를 암호화하는 dna, 이의 제조방법 및 용도
NO976094D0 (no) Nye peptider avledet av humant varmesjokkprotein 60 for behandling av diabetes, fremgangsmåte og sett
ATE537186T1 (de) P53-bindendes polypeptid
ATE293254T1 (de) Modulierung von mlk- (multiple lineage kinase) proteinen
WO1999033981A3 (fr) Proteines contenant des sequences-signaux humaines
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
DE68909304D1 (de) Aminosäuren für der Behandung neurodegenerativer Störungen.
WO2004089302A3 (fr) Polypeptides posh, complexes et procedes correspondants
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
DE3888715D1 (de) Reg-Gen und dadurch kodiertes Protein.
NO920524L (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin